Evidence map›Paper›PMID 34342074›Full record

ArticleAPMIS : acta pathologica, microbiologica, et immunologica Scandinavica2021

Analyses of ABO blood groups with susceptibility and symptomatic variations of COVID-19 infection, a questionnaire-based survey.

Asma Komal, Mamoona Noreen, Junaid Akhtar, Muhammad Imran, Muhsin Jamal, Muhammad Atif, Juma Khan, Muhammad Roman, Faiz Ul Haq, Usman Aftab and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 2 countries.

Asma KomalDepartment of Zoology, The Women University Multan, Multan, Pakistan.
Mamoona NoreenDepartment of Zoology, The Women University Multan, Multan, Pakistan.
Junaid AkhtarDepartment of Microbiology, University of Health Sciences, Lahore, Pakistan.
Muhammad ImranDepartment of Microbiology, University of Health Sciences, Lahore, Pakistan.
Muhsin JamalDepartment of Microbiology, Abdul Wali Khan University, Mardan, Pakistan.
Muhammad AtifDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, Jouf University, Kingdom of Saudi Arabia.
Juma KhanMolecular Laboratory, Sheikh Khalifa Bin Zayyed Hospital, Quetta, Pakistan.
Muhammad RomanDepartment of Microbiology, University of Health Sciences, Lahore, Pakistan.
Faiz Ul HaqDepartment of Microbiology, University of Health Sciences, Lahore, Pakistan.
Usman AftabDepartment of Pharmacology, University of Health Sciences, Lahore, Pakistan.
Abdul GhaffarDepartment of Pharmacology, University of Health Sciences, Lahore, Pakistan.
Yasir WaheedFoundation University Medical College, Foundation University Islamabad, DHA-I, Islamabad, Pakistan.
University of Health Sciences Lahore · PKThe Women University Multan · PKAbdul Wali Khan University Mardan · PKAl Jouf University · SAFoundation University Islamabad · PKShaikh Zayed Hospital · PKUniversity of Sargodha · PK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coronavirus disease 2019 (COVID-19) is a novel respiratory disease that has led to a global pandemic and created a havoc. The COVID-19 disease severity varies among individuals, depending on fluctuating symptoms. Many infectious diseases such as hepatitis B and dengue hemorrhagic fever have been associated with ABO blood groups. The aim of this study was to explore whether ABO blood groups might serve as a risk or a protective factor for COVID-19 infection. Moreover, the symptomatic variations of COVID-19 infection among the individuals with different blood groups were also analyzed. An online questionnaire-based survey was conducted in which 305 partakers were included, who had successfully recovered from coronavirus infection. The ABO blood groups of 1294 healthy individuals were also taken as a control. The results of the current study demonstrated that antibody A containing blood groups (blood group B, p-value: 0.049 and blood group O, p-value: 0.289) had a protective role against COVID-19 infection. The comparison of symptomatic variations among COVID-19-infected subjects showed that blood group O subjects had lower chances of experiencing severe symptoms relating to respiratory distress, while subjects with AB blood group were more prone to develop symptoms, but the differences in both groups were found to be statistically non-significant. In conclusion, subjects who do not have anti-A antibodies in their serum (i.e., subjects with group A and AB) are more likely to be infected with COVID-19. The current data showed that there was no significant association of signs and symptoms variations of COVID-19 infection among individuals with different blood groups.

Indexed as

ABO Blood-Group SystemAdolescentAdultAge DistributionCase-Control StudiesCOVID-19Disease SusceptibilityFemaleHumansMaleMiddle AgedRisk FactorsSex DistributionSurveys and QuestionnairesYoung AdultABO Blood-Group SystemassociationbloodCOVID-19pandemicpronesymptoms

Identifiers

PMID34342074
PMCPMC8444696
OpenAlexW3188019642

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.